SCHEMBL1102887

SCHEMBL1102887

c1ccc2c(-c3ccncc3)c3ncccc3c(-c3ccncc3)c2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 7/20 0.45
NPC1 O15118 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
HSP90AA1 P07900 1/20 0.45
IMPDH2 P12268 2/20 0.42
MAPK13 O15264 1/20 0.42
MAPK12 P53778 1/20 0.42
MAPK11 Q15759 1/20 0.42
NOTUM Q6P988 1/20 0.41
KDM4E B2RXH2 2/20 0.41
RAB9A P51151 1/20 0.41
MAPT P10636 2/20 0.37
LMNA P02545 2/20 0.37
RAF1 P04049 1/20 0.37
DYRK1A Q13627 1/20 0.37
MAPK1 P28482 1/20 0.37
HSD17B10 Q99714 1/20 0.37
ALDH1A1 P00352 1/20 0.37
CKS1B P61024 1/20 0.37
SKP2 Q13309 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1102824 0.88 L3MBTL1 (0.43) NPC1L3MBTL1HSP90AA1KDM4EMAPT
SCHEMBL1103081 0.86 L3MBTL1 (0.42) NPC1L3MBTL1HSP90AA1KDM4EMAPT
SCHEMBL1103120 0.86 L3MBTL1 (0.42) NPC1L3MBTL1HSP90AA1KDM4EMAPT
SCHEMBL1103115 0.86 L3MBTL1 (0.42) NPC1L3MBTL1HSP90AA1KDM4EMAPT
SCHEMBL1103109 0.86 L3MBTL1 (0.42) NPC1L3MBTL1HSP90AA1KDM4EMAPT
SCHEMBL1102949 0.85 L3MBTL1 (0.41) NPC1L3MBTL1HSP90AA1NOTUMKDM4E
SCHEMBL1103097 0.85 L3MBTL1 (0.41) NPC1L3MBTL1HSP90AA1NOTUMKDM4E
SCHEMBL1102990 0.85 L3MBTL1 (0.41) NPC1L3MBTL1HSP90AA1NOTUMKDM4E
SCHEMBL1102789 0.85 L3MBTL1 (0.41) NPC1L3MBTL1HSP90AA1NOTUMKDM4E
SCHEMBL11910167 0.83 NOTUM (0.57) MAPK14NPC1IMPDH2MAPK13MAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 MAPK14 3348/4885NPC1 1582/4885L3MBTL1 1629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.